Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jun 15, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 16, 2026
DirectorIndirect holdingGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001231919-26-000640
Filed / recorded
Jun 16, 2026, 12:22 AM UTC
Added to OQRO
Oct 7, 2026, 5:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
LENZ Therapeutics, Inc.
Issuer CIK
1815776
Ticker
LENZ
Reporting person
RA CAPITAL MANAGEMENT, L.P.
Relationship
Director, 10% owner
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Jun 15, 2026
Transaction code
A
Shares / units
22,100
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
22,100
Ownership form
Indirect — See footnotes
Amendment
No
Footnotes from the filing
One hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders, subject to Dr. Scheiner's continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date.
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.
Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.